-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TDI01 can be treated in all aspects of fibrosis development by inhibiting ROCK2 and at the same time inhibiting fibrosis, anti-inflammatory and immunomodulation.
research data was highly recognized by Professor Scott L. Friedman, Director of the Hepatology Center at Mount Sinai Hospital in the United States, and Professor Dai Huaping, Director of Respiratory and Critical Illness at Sino-Japanese Friendship Hospital.
, at the same time, a joint study of pulmonary fibrosis markers is being conducted with Professor Ding sen, Distinguished Professor of the Second Hospital of Huaxi And The National Key Laboratory for Biological Therapy, and Professor Charles A Powell, Director of Respiratory Medicine at Mount Sinai Hospital in the United States.
at present, the global lack of effective drugs to treat fibrosis, non-alcoholic fatty hepatitis caused by hepatic fibrosis in the world has not been approved varieties, a variety of interstitial pulmonary disease caused by pulmonary fibrosis treatment methods are also very limited. TDI01, a new target developed by
Ted Pharmaceuticals, will provide new treatment options in this critical clinical area.
.